-
Mashup Score: 0Mezigdomide Plus Dexamethasone Elicits Responses With Acceptable Safety in R/R Myeloma - 8 month(s) ago
Treatment with combination of mezigdomide and dexamethasone produced responses with a safety profile that consisted primarily of myelotoxic adverse effects in heavily pretreated patients with relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Mezigdomide Plus Dexamethasone Elicits Responses With Acceptable Safety in R/R Myeloma - 8 month(s) ago
Treatment with combination of mezigdomide and dexamethasone produced responses with a safety profile that consisted primarily of myelotoxic adverse effects in heavily pretreated patients with relapsed/refractory multiple myeloma.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Treatment with combination of mezigdomide and dexamethasone produced responses with a safety profile that consisted primarily of myelotoxic adverse effects in heavily pretreated patients with relapsed/refractory multiple myeloma. @NEJM #mmsm #OncClub https://t.co/WuL70nof6q
-
-
Mashup Score: 0Further Research Needed to Inform the Management of Post-Chemo Residual Nonretroperitoneal Disease in Testicular Cancer - 10 month(s) ago
Jennifer M. King, MD, expands on the design and methodology of a retrospective study of teratoma in residual nonretroperitoneal disease post-chemotherapy and key findings regarding the correlation between teratoma in the primary tumor and rates of post-chemotherapy teratoma in residual non–nonretroperitoneal disease.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Teratoma in the primary tumor site was associated with a higher incidence of teratoma in residual nonretroperitoneal (non–RP) disease post-chemotherapy, according to findings from a retrospective study. @JenniferKingMD @IUMedSchool #OncClub #tscsm https://t.co/yUfF0hwQOx https://t.co/SIIZc8lPGj
-
-
Mashup Score: 0Further Research Needed to Inform the Management of Post-Chemo Residual Nonretroperitoneal Disease in Testicular Cancer - 10 month(s) ago
Jennifer M. King, MD, expands on the design and methodology of a retrospective study of teratoma in residual nonretroperitoneal disease post-chemotherapy and key findings regarding the correlation between teratoma in the primary tumor and rates of post-chemotherapy teratoma in residual non–nonretroperitoneal disease.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Further Research Needed to Inform the Management of Post-Chemo Residual Nonretroperitoneal Disease in Testicular Cancer @JenniferKingMD @IUMedSchool #OncClub #tscsm https://t.co/EVToYaiswF
-
-
Mashup Score: 3Resection Should be Considered for Residual Non-Retroperitoneal Disease in Post-Chemo NSGCTs - 11 month(s) ago
Although patients with metastatic nonseminomatous germ-cell tumors who had teratoma in the primary tumor were found to have a higher rate of teratoma in residual non-retroperitoneal disease following chemotherapy, those without teratoma in the primary tumor could have teratoma or active testicular germ-cell tumors in residual disease post-chemotherapy and should be considered for resection.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Resection Should be Considered for Residual Non-Retroperitoneal Disease in Post-Chemo NSGCTs @JenniferKingMD @IUCancerCenter #OncClub #tscsm #oncology https://t.co/leoEiRIXi7
-
-
Mashup Score: 1Isolated Hepatic Perfusion With Melphalan Improves PFS, ORR for Patients With Isolated Uveal Melanoma Liver Metastases - 1 year(s) ago
A one-time treatment with isolated hepatic perfusion with melphalan improved median progression-free survival compared with best alternative treatment for patients with previously untreated isolated liver metastases from uveal melanoma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Isolated Hepatic Perfusion With Melphalan Improves PFS, ORR for Patients With Isolated Uveal Melanoma Liver Metastases @JCO_ASCO #OncClub #melsm #oncology https://t.co/tL1OMHEeeN
-
-
Mashup Score: 0Multiple Factors Need to Be Addressed to Improve Late Mortality for Survivors of Childhood Cancer - 1 year(s) ago
Matthew J. Ehrhardt, MD, MS, discusses the importance of taking a multifactorial approach to improve long-term outcomes for survivors of childhood cancer, and expands on the findings from the study of the factors associated with risk of late mortality.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Multiple Factors Need to Be Addressed to Improve Late Mortality for Survivors of Childhood Cancer @StJudeResearch #OncClub #oncology https://t.co/irbMpLHPvb
-
-
Mashup Score: 2Post-Transplant KRd Maintenance May Allow for Superior Outcomes in Newly Diagnosed Multiple Myeloma - 1 year(s) ago
Andrzej Jakubowiak, MD, PhD, highlighted several key studies that influenced the development and design of the ATLAS trial, introduced conclusions from the initial efficacy data, and discussed how ongoing analysis could further contextualize and inform post-transplant treatment approaches in multiple myeloma.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Post-Transplant KRd Maintenance May Allow for Superior Outcomes in Newly Diagnosed Multiple Myeloma @UCCancerCenter #OncClub #mmsm https://t.co/EoMmC3oOll
-
-
Mashup Score: 0MRI-Guided SBRT Could Represent Safer, More Precise Radiotherapy Option for Prostate Cancer - 1 year(s) ago
Amar U. Kishan, MD, discusses the safety results of MRI-guided SBRT compared with the current standard of care, highlights the benefits of using an MRI to guide radiation for patients with prostate cancer, and explains other areas where MRI-guided SBRT could explored.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
MRI-Guided SBRT Could Represent Safer, More Precise Radiotherapy Option for Prostate Cancer @AmarUKishan @UCLAJCCC #pcsm #OncClub https://t.co/VW7zSFb2p4
-
-
Mashup Score: 0
Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Immunotherapy followed by targeted therapy has emerged as the new standard of care for patients with melanoma with BRAF V600 mutations. @AndrewPecoraMD @HMHNewJersey #mmsm #OncClub https://t.co/u1mDFgF0mt
-
Data from a phase 1/2 trial showed that patients with R/R multiple myeloma in the phase 1 dose-escalation cohort experienced an ORR of 25% with mezigdomide and dexamethasone. @NEJM #mmsm #OncClub https://t.co/Zg4qyLzZ3H https://t.co/yRbGMbRZIN